124 related articles for article (PubMed ID: 38646675)
1. Assessing HER2 status in breast cancer through next-generation sequencing of circulating tumor cells.
Di Cosimo S; Silvestri M; De Marco C; Reduzzi C; Folli S; De Santis MC; Cappelletti V
Int J Biol Markers; 2024 Jun; 39(2):184-185. PubMed ID: 38646675
[No Abstract] [Full Text] [Related]
2. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Wang C; Mu Z; Ye Z; Zhang Z; Abu-Khalaf MM; Silver DP; Palazzo JP; Jagannathan G; Fellin FM; Bhattacharya S; Jaslow RJ; Tsangaris TN; Berger A; Neupane M; Cescon TP; Lopez A; Yao K; Chong W; Lu B; Myers RE; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2020 Jun; 181(3):679-689. PubMed ID: 32367460
[TBL] [Abstract][Full Text] [Related]
3. HER2 as marker for the detection of circulating tumor cells.
Müller V; Pantel K
Breast Cancer Res Treat; 2009 Oct; 117(3):535-7. PubMed ID: 19115105
[No Abstract] [Full Text] [Related]
4. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
5. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization and heterogeneity of circulating tumor cells in breast cancer.
Jakabova A; Bielcikova Z; Pospisilova E; Matkowski R; Szynglarewicz B; Staszek-Szewczyk U; Zemanova M; Petruzelka L; Eliasova P; Kolostova K; Bobek V
Breast Cancer Res Treat; 2017 Dec; 166(3):695-700. PubMed ID: 28815327
[TBL] [Abstract][Full Text] [Related]
9. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
10. Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer.
Volmer LL; Dannehl D; Matovina S; Taran FA; Walter CB; Wallwiener M; Brucker SY; Hartkopf AD; Engler T
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892097
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
[TBL] [Abstract][Full Text] [Related]
12. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
14. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
[TBL] [Abstract][Full Text] [Related]
15. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
[TBL] [Abstract][Full Text] [Related]
17. Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy.
Ziogas DE; Spiliotis J; Lykoudis EG; Zografos GC; Roukos DH
Future Oncol; 2017 Jan; 13(2):113-116. PubMed ID: 27581662
[No Abstract] [Full Text] [Related]
18. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.
Krishnamurthy S; Bischoff F; Ann Mayer J; Wong K; Pham T; Kuerer H; Lodhi A; Bhattacharyya A; Hall C; Lucci A
Cancer Med; 2013 Apr; 2(2):226-33. PubMed ID: 23634290
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells in metastatic breast cancer patients.
Sanislo L; Vertakova-Krakovska B; Kuliffay P; Brtko J; Galbava A; Galbavy S
Endocr Regul; 2011 Jul; 45(3):113-24. PubMed ID: 21793623
[TBL] [Abstract][Full Text] [Related]
20. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
